ReviewAmerican journal of stem cells2016
Current stem cell based therapies in diabetes.
Review in American journal of stem cells, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Challenges with Cell-based Therapies for Type 1 Diabetes Mellitus.Stem cell reviews and reports · 2023Review
- β cell regeneration and novel strategies for treatment of diabetes (Review).Biomedical reports · 2022Review
- Nanoparticles for Stem Cell Tracking and the Potential Treatment of Cardiovascular Diseases.Frontiers in cell and developmental biology · 2021Review
- The Role of Mesenchymal Stromal Cells-Derived Small Extracellular Vesicles in Diabetes and Its Chronic Complications.Frontiers in endocrinology · 2021Review
- Human Wharton's Jelly-Derived Mesenchymal Stromal Cells Primed by Tumor Necrosis Factor-α and Interferon-γ Modulate the Innate and Adaptive Immune Cells of Type 1 Diabetic Patients.Frontiers in immunology · 2021Article
- The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis.Aging and disease · 2020Review
- Automation, Monitoring, and Standardization of Cell Product Manufacturing.Frontiers in bioengineering and biotechnology · 2020Review
- The Role of Extracellular Vesicles in β-Cell Function and Viability: A Scoping Review.Frontiers in endocrinology · 2020Article
- Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes.Stem cell research & therapy · 2019Review
- Tonsil-derived stem cells as a new source of adult stem cells.World journal of stem cells · 2019Review
- Article
- Generation of a Transgenic Zebrafish Model for Pancreatic Beta Cell Regeneration.Galen medical journal · 2019Article
- Transcription Factor Levels after Forward Programming of Human Pluripotent Stem Cells with GATA1, FLI1, and TAL1 Determine Megakaryocyte versus Erythroid Cell Fate Decision.Stem cell reports · 2018Article
- Oxygen transporter for the hypoxic transplantation site.Biofabrication · 2018Article
- Regenerating β cells of the pancreas - potential developments in diabetes treatment.Expert opinion on biological therapy · 2018Review
- Regenerative Medicine and Diabetes: Targeting the Extracellular Matrix Beyond the Stem Cell Approach and Encapsulation Technology.Frontiers in endocrinology · 2018Review
- Addressing Stem Cell Therapeutic Approaches in Pathobiology of Diabetes and Its Complications.Journal of diabetes research · 2018Review
- Discovery of a stem-like multipotent cell fate.American journal of stem cells · 2018Article
- Current approaches in regenerative medicine for the treatment of diabetes: introducing CRISPR/CAS9 technology and the case for non-embryonic stem cell therapy.American journal of stem cells · 2018Review
- Establishment of Insulin-Producing Cells From Human Embryonic Stem Cells Underhypoxic Condition for Cell Based Therapy.Frontiers in cell and developmental biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a disease with wide-ranging personal and societal impacts that has been managed medicinally for over half a century. Since the discovery of stem cells, pancreatic islet regeneration has become a central target for clinical application that has the potential to decrease or eliminate the need for insulin administration and adjunctive medications. The discovery of alternative routes to pluripotency that bypass the ethical implications of embryonic stem cells has significantly expanded the horizons of stem cell based therapy. Engraftment of mature insulin producing cells derived from induced pluripotent stem cells may represent the most promising treatment strategy for diabetic patients with impaired β-cell function. These cells are easily accessible and have been shown to closely mimic endogenous β-cell function
Indexed as
Identifiers
27853630PMC5107653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.